Explore a next step for moderate to severe endometriosis pain relief

The first FDA-approved oral treatment for moderate to severe endometriosis pain in over a decade¹

See how ORILISSA works

Learn about the GnRH receptor
antagonist mechanism of
action (MOA).¹

Available in two oral dosages:

150 mg QD 200 mg BID

Choose the option most appropriate for her based on severity of symptoms and treatment objectives.¹

the first FDA-approved oral gonadotropin-releasing hormone (GnRH) antagonist for the treatment of moderate to severe endometriosis pain in over a decade

Dyspareunia

Non-menstrual pelvic pain

Dysmenorrhea

Dysmenorrhea

(150 mg or 200 mg)

Non-menstrual Pelvic Pain

(150 mg or 200 mg)

Dyspareunia^*

(200 mg only)

*Statistical significance for dyspareunia was not achieved with the 150 mg dose of ORILISSA.

See how ORILISSA works

Back to top